|
Publications |
|
Suzuki, E., Kapoor, V., Cheeung, H.K., Ling, L., DeLong, P., Kaiser, L.R., Albelda, S.M. Soluble Type II Transforming Growth Factor-b Receptor Inhibits Both Small and Large Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Anti-tumor Immunity. Clinical Cancer Research, 10:5907-5918, 2004. Tanaka, T., DeLong, P.A., Amin, K., Henry, A., Kruklitis, R., Kapoor, V., Kaiser, L.R., Albelda, S.M. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor, Rofecoxib: Potential value as adjuvant therapy after surgery. Annals of Surgery, 241:168-178, 2005 DeLong, P., Carroll, R.G., Henry, A.C., Tanaka, T., Ahmad, S., Leibowitz, M., Sterman, D.H., June, C.H., Albelda, S.M., Vonderheide, R.H. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biology and Therapy, 4; 342-346, 2005. Vachani, A, Singhal, S., Antin-Ozerkis, Kaiser, L.R., Albelda, S.M. Prognostic implications of cell cycle, aopoptosis, and angiogenesis biomarkers in non-small cell lung cancer. Clin Cancer Res. 11:3974-3986, 2005. Sterman DH, Recio A, Vachani, A., Sun, J., Cheung, L., DeLong P, Amin KM, Litzky LA, Wilson JM, Kaiser LR, Albelda SM. Long-Term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High Dose Adenovirus Herpes Simplex Thymidine kinase (HSVtk)/ Ganciclovir (GCV) Suicide Gene Therapy. Clinical Cancer Research, 11:7444-7453, 2005. Suzuki, E., Kapoor, V., Jassar, A., Kaiser, LR., Albelda, S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances anti-tumor immune activity. Clinical Cancer Research, 11:6713-6721, 2005. Wilderman, M., Sun, J., Khan, M., Vachani, A., Suzuki, E., Kinnery, P., Sterman, D., Kaiser, L., Albelda, S.M. Intrapulmonary interferon-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of lung adenocarcinoma via a combination of direct toxicity, NK cell, and CD8 T-cell mediated effects. Cancer Research, 65:8379-8387, 2005. Jassar, A., Suzuki, E., Kapoor, V., Sun, J., Silverberg, M., Cheung, L., Burdick,, M., Strieter, R., Ching, L-M., Kaiser, L.R., Albelda, S.M. Activated Tumor-Associated Macrophages and CD8+ T-cells are the Key Mediators of Anti-tumor Effects of the Vascular Disrupting Agent 5,6 Di-methylxanthenone-4-acetic Acid (DMXAA) in Murine Models of Lung Cancer and Mesothelioma”. Cancer Research, 65:11752-11761, 2005. Haas, A., Sun, J., Vachani, A., Wallace, A.F., Silverberg, M., Kapoor, V., Albelda, S.M. Cyclooxygenase-2 Inhibition augments efficacy of a cancer vaccine. Clinical Cancer Research, 12:214-222, 2006. Wilderman, M., Kim,, S., Gillespie, C.T., Sun, J., Kapoor, V., Vachani, A., , Sterman, D., Kaiser, L., Albelda, S.M. Blockade of TNFa Decreases Both Inflammation and Efficacy of Intrapulmonary Ad.IFN Beta Immunotherapy in an Orthotopic Model of Bronchogenic Lung Cancer. Molecular Therapy, 13:910-917, 2006. Sterman, D.H., Gillespie, C.T., Carroll, R., Coughlin, C.M., Lord, E.M., Sun, J., Haas, A., Recio, A., Kaiser, L.R., Coukos, G., June, C.H., Albelda, S.M., and Vonderheide, R.H., Interferon-beta adenoviral gene therapy in a patient with ovarian cancer. Nature Clinical Oncology, 3:633-639, 2006. Suzuki E , Kim, S, Cheung, HK, Corbley, M, Zhang X, Sun, L, Shan F, Singh, J., Lee, WC, Albelda,SM, Ling, LE. A Novel Small Molecule Inhibitor of TGF-beta type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth in vivo and Prevents the Extent of Tumor Recurrence After Surgical Resection. Cancer Research, 67:2351-2359, 2007. Vachani, A., Nebozhyn, M., Singhal, S., Beers, M., Litzky, L., Muschel, R., Powell, C., Gaffney, P. Kaiser, L., Marron J., Showe, M.,., Albelda, S., Showe, L M. Identification of 10 Gene Classifier for Head and Neck Squamous Cell Carcinoma and Lung Squamous Cell Carcinoma: Towards a Distinction between Primary and Metastatic Squamous Cell Carcinoma of the Lung. Clinical Cancer Research, 13:2905-2915, 2007. Vachani, A., Sterman D.H., Albelda, SM. Cytokine gene therapy for malignant pleural mesothelioma. Journal of Thoracic Oncology, 2: 2007. Suzuki, E., Sun, J., Kapoor, V., Jessar, A., Albelda, S.M., Gemcitabine Has Significant Immunomodulatory Activity in Murine Tumor Models Independent of its Cytotoxic Effects. Cancer Biology and Therapy; 6:880-5, 2007. Sterman, D.H., Recio, A.R., Carroll, R.G., Gillespie, C.T., Haas A., Vachani, A., Kapoor V., Sun, J., Hodinka, R., Brown, J.L., Corble,y M.J., Parr, M., Ho M., Pastan I., Machuzak, M., Benedict, W., Zhang, X, Lord, E.M., Litzky, L.A., Heitjan, D.F., June C.H., Kaiser L.R., Vonderheide, R.H., and Albelda, S.M. A Phase I Clinical Trial of Single-Dose Intrapleural Interferon-Beta Gene Transfer For Malignant Mesothelioma and Metastatic Pleural Effusions: High Rate of Anti-Tumor Immune Responses. Clinical Cancer Research, 13:4456-4466, 2007. Wallace, A., LaRosa, D.F, Kapoor, V. Sun, J., Cheng, G, Jassar, A., Blouin, A., Ching, L., Albelda, S.M., The Vascular Disrupting Agent, 5,6 Di-methylxanthenone-4-acetic Acid (DMXAA), Directly Activates Dendritic Cells Through a MyD88-indpendent Mechanism and Generates Anti-Tumor Cytotoxic T-Lymphocytes. Cancer Research, 67:7011-7019, 2007 Sinha, P., Clements, V.K., Bunt, S.K., Albelda, S.M., Ostrand-Rosenberg, S. Cross-talk between Myeloid-derived Suppressor Cells and Macrophages Subverts Tumor Immunity towards a Type-2 Responses. Journal of Immunology, 179:977-83, 2007. Kim, S. Fridlender, G, Dunn R, Kehry, M.R., Kapoor, V, Blouin A., Kaiser L.R., Albelda, S.M. B Cell Depletion Using an anti-CD20 Antibody Augments Anti-tumor Immune Responses and Immunotherapy in Murine Models. Journal of Immunotherapy, 31: 446-457, 2008. Wallace, A., Kapoor, V., Sun, J., Mrass, P., Weninger, W., Heitjan, D.F., June, C., Kaiser, L.R., Ling, L.E., Albelda, S.M. TGF-b receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid tumors. Clin. Cancer Res., 14: 3966-3974, 2008. Carroll RG, Carpenito C, Shan X, Danet-Desnoyers G, Liu R, Jiang S, Albelda SM, Golovina T, Coukos G, Riley JL, Jonak ZL, June CH. Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. PLoS ONE. 2008 Sep 26;3(9):e3289. Kim, S, Buchlis, G., Fridlender, Z.G., Sun, J., Kapoor, V., Cheng, G, Haas, A., Cheung, H.K., Zhang, X., Corbley, M, Kaiser, LR, Ling, LE., Albelda, SM. Systemic Blockade of Transforming Growth Factor-b Signaling Augments the Efficacy of Immunogene Therapy. Cancer Research, 2008 Dec 15;68(24):10247-56
|
|
Thoracic Oncology Research Laboratory |
